According to recent evidence, HMGB1 serum levels and the relative levels of its different isoforms (hyper-acetylated and non-acetylated HMGB1) can distinguish MM patients from asbestos-exposed individuals and unexposed controls with 100% sensitivity and specificity, outperforming existing biomarkers (mesothelin, fibulin-3, and osteopontin), whereas HMGB1 combined with fibulin-3 improves differential diagnosis [13]. Here, HMGB1 is linked to Miyoshi myopathy.